Its dysregulation contributes to hallmark features of metabolic disease, including insulin resistance, hepatic steatosis, and mitochondrial dysfunction, positioning YY1 as a promising therapeutic target in metabolic disorders (Table 2). Here, YY1 is linked to fatty liver disease.